Jazz Pharmaceuticals plc
Jazz Pharmaceuticals develops and commercializes pharmaceutical products for unmet medical needs. Products include Xywav, Xyrem, Epidiolex, Zepzelca, Rylaze, Enrylaze, Defitelio, and Vyxeos. The company also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma. Jazz Pharmaceuticals has agreements with XL-protein GmbH, Redx Pharma plc, and Autifony Therapeutics Limited for preclinical activities. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Overview
Strengths
- Current Price to Earnings Ratio (11.57) is lower than the sector mean (91.15).
- Price to book ratio (1.58) is lower than the sector mean (24.44).
- The company has high returns. ROIC (13.68%) is higher than the sector mean (6.02%).
- EV/EBITDA (7.34) is lower than the sector mean (85.60).
- EV/EBIT (14.37) is lower than the sector mean.
- Price to free cash flow (4.81) is lower than the sector mean.
- Strong EBITDA Margin of 34.08%.
Weaknesses
- With a depreciation Potential of -32.74%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (2.67) is higher than the sector mean.
Key Financial Data
| Indicator | Value |
|---|
| PER | 11.6 |
| EV/EBITDA | 7.3 |
| Price/Free Cash Flow' | 4.8 |
| ROIC | 13.7% |
| Net Debt/EBITDA | 2.7 |